IGC Pharma (NYSE American: IGC)/b) announced that Ascendiant Capital Markets raised its price target to in a new equity research report.
The report, focused on clinical progress and potential 2026 catalysts, centers on IGC-AD1, now in the Phase 2 CALMA trial for agitation in Alzheimer’s disease.
Loading...
Loading translation...
Positive
None.
Negative
None.
News Market Reaction – IGC
-4.68%
1 alert
-4.68%Session close to close
$28.53MMarket Cap
0.0xRel. Volume
In the Jun 9 session, IGC declined 4.68%, reflecting a moderate negative market reaction.
This announcement highlights Ascendiant’s higher price target of $5.50, tied to IGC’s Phase 2 CALMA ...
Analysis
This announcement highlights Ascendiant’s higher price target of $5.50, tied to IGC’s Phase 2 CALMA trial and anticipated 2026 clinical catalysts, without providing new data. Historically, updates around CALMA sites, enrollment, and related outreach have produced mixed market reactions. Investors may watch for actual topline Phase 2 results, further financing developments, and any changes to analyst coverage or targets as more concrete drivers of sentiment than this standalone research note.
Key Figures
Price target:$5.50 per shareTrial phase:Phase 2Catalyst year:2026
3 metrics
Price target$5.50 per shareAscendiant Capital Markets updated equity research report
Trial phasePhase 2CALMA trial of IGC-AD1 for agitation in Alzheimer’s disease
Catalyst year2026Ascendiant cites additional 2026 clinical data and progress as catalysts
Added Kerwin Medical Center site with ~80% CALMA enrollment and neurology expertise.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Pattern Detected
Recent IGC news often elicits muted or mixed reactions, with some positive clinical updates followed by negative price moves and only occasional strong rallies.
Recent Company History
Over the last few months, IGC has repeatedly highlighted progress in its Phase 2 CALMA trial of IGC-AD1 for agitation in Alzheimer’s, including new sites in Dallas and Mount Sinai and caregiver engagement efforts. An April clinical-site addition saw a +7.66% move, while other CALMA and outreach updates drew modest negative reactions. The May Q1 2026 results combined financial details with trial progress and prompted only a small gain. Today’s analyst price-target increase builds on that steady clinical narrative without introducing new trial data.
Key Terms
equity research report, price target, clinical-stage, phase 2, +1 more
5 terms
equity research reportfinancial
"Ascendiant Capital Markets has issued an updated equity research report on the Company"
A written analysis produced by financial analysts that evaluates a company's business, financial health, earnings prospects and stock valuation, often including a buy/hold/sell recommendation. Investors use it as a compact guide to a stock's strengths, risks and likely future performance — like a mechanic's inspection report for a car, it helps decide whether to buy, hold or sell and highlights what could change the outlook.
price targetfinancial
"raising its price target to $5.50 per share"
A price target is an analyst’s estimate of the future value of a stock, typically expressed as a single number for a set time frame. It matters to investors because it acts like an expected selling price when appraising a house—helping people decide whether a stock looks cheap, fairly priced, or expensive compared with current market price and guiding buy, hold or sell decisions; it is an opinion, not a guarantee.
"a clinical-stage biotechnology company developing therapeutics for Alzheimer's disease"
Clinical-stage describes a drug, therapy, or company whose product is being tested in human trials but has not yet received regulatory approval. For investors, it signals that the project has moved beyond lab work into real-world testing—meaning higher potential reward if trials succeed but also clear risks from trial setbacks, costs, and regulatory delay; think of it like a prototype car on public road tests that could either prove its value or reveal problems that stop it from reaching production.
phase 2medical
"IGC-AD1, is currently being evaluated in the Phase 2 CALMA clinical trial"
Phase 2 is the mid-stage clinical trial where a new drug or treatment is tested in a larger group of patients to see if it works and to keep checking safety after initial human testing. Think of it as a field test that proves whether a product actually delivers its promised benefit. Investors watch Phase 2 closely because its results strongly influence a medicine’s chances of reaching the market, the size of its potential sales, and the company’s valuation.
clinical trialmedical
"Phase 2 CALMA clinical trial for agitation associated with Alzheimer's disease"
A clinical trial is a carefully controlled study in which a new medicine, medical device, or treatment is tested on people to see if it is safe and effective. For investors it matters because trial results determine whether a product can win regulatory approval and reach patients, much like a road test decides if a new car can be sold; positive or negative results can sharply change a company’s prospects and stock value.
POTOMAC, MD / ACCESS Newswire / June 9, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company developing therapeutics for Alzheimer's disease, today announced that Ascendiant Capital Markets has issued an updated equity research report on the Company, raising its price target to $5.50 per share.
According to Ascendiant, the updated report highlights the Company's clinical progress and states that additional clinical data and progress in 2026 could serve as strong catalysts for IGC Pharma's stock.
IGC Pharma's lead program, IGC-AD1, is currently being evaluated in the Phase 2 CALMA clinical trial for agitation associated with Alzheimer's disease. The Company continues to advance CALMA toward its next operational and clinical milestones.
The Ascendiant report, entitled "Reports Q1 2026. We believe more positive clinical data and progress in 2026 to be strong catalysts for stock. Raising P/T to $5.50," may be obtained directly from Ascendiant Capital Markets: Link.
All reports on IGC Pharma prepared by analysts represent the views of those analysts and are not necessarily those of IGC Pharma. IGC does not endorse, adopt, or guarantee the accuracy, completeness, conclusions, projections, or recommendations contained in any analyst report and undertakes no obligation to update or correct such information.
About IGC Pharma (dba IGC):
IGC Pharma (NYSE American:IGC) is a clinical-stage biotechnology company leveraging AI to develop innovative treatments for Alzheimer's and metabolic disorders. Our lead asset, IGC-AD1, is a therapy currently in a Phase 2 trial (CALMA) for agitation in Alzheimer's dementia. Our pipeline includes TGR-63, targeting amyloid plaques, and early-stage programs focused on neurodegeneration, tau proteins, and metabolic dysfunctions. We integrate AI to accelerate drug discovery, optimize clinical trials, and enhance patient targeting. With a complete patent portfolio and a commitment to innovation, IGC Pharma is advancing breakthrough therapies.
Forward-Looking Statements:
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are based on current expectations and involve risks and uncertainties that could cause actual results to differ materially, including risks related to the Company's ability to complete enrollment in its Phase 2 CALMA trial within anticipated timeframes, demonstrate safety and efficacy, the timing of data readouts, regulatory approvals, and other factors discussed in the Company's filings with the U.S. Securities and Exchange Commission (SEC), including its most recent Annual Report on Form 10-KT. The Company undertakes no obligation to update these statements.
Why did Ascendiant Capital Markets raise the IGC (NYSE American: IGC) price target to $5.50 in June 2026?
Ascendiant raised its IGC price target to $5.50, citing clinical progress and expected 2026 catalysts. According to IGC Pharma, the report highlights advancing Alzheimer’s program IGC-AD1 and suggests additional clinical data in 2026 could support the stock.
What clinical trial supports Ascendiant’s new $5.50 price target for IGC Pharma (IGC)?
The new price target is supported by progress in the Phase 2 CALMA trial of IGC-AD1. According to IGC Pharma, CALMA evaluates IGC-AD1 for agitation associated with Alzheimer’s disease and is moving toward upcoming operational and clinical milestones.
What is IGC-AD1 and how is it being studied by IGC Pharma (IGC)?
IGC-AD1 is IGC Pharma’s lead program, developed for agitation in Alzheimer’s disease. According to IGC Pharma, IGC-AD1 is currently being evaluated in the Phase 2 CALMA clinical trial, with the company advancing the study toward its next milestones.
What 2026 catalysts does Ascendiant expect for IGC Pharma (IGC) stock?
Ascendiant expects additional clinical data and progress in 2026 to be potential catalysts for IGC stock. According to IGC Pharma, the updated research report links these anticipated developments to the revised $5.50 price target.
Where can investors access the Ascendiant research report on IGC Pharma (IGC) and the $5.50 target?
Investors can obtain the Ascendiant report directly from Ascendiant Capital Markets. According to IGC Pharma, the report is titled “Reports Q1 2026. We believe more positive clinical data and progress in 2026 to be strong catalysts for stock. Raising P/T to $5.50.”
Does IGC Pharma (IGC) endorse Ascendiant’s $5.50 price target and research conclusions?
IGC Pharma does not endorse or adopt Ascendiant’s conclusions, projections, or recommendations. According to IGC Pharma, analyst reports reflect only the analysts’ views, and the company does not guarantee their accuracy or undertake obligations to update or correct them.
